Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7235538 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Patent 7235538 was granted and assigned to Novo Nordisk on June, 2007 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

72355380

Patent Inventor Names

Lise Brown Christiansen0

Jane Marie Lundbeck0

Christian K. Sams0

Anders Bendtz Kanstrup0

Marit Kristiansen0

Date of Patent

June 26, 2007

Patent Application Number

106213020

Date Filed

July 17, 2003

Patent Citations Received

‌

US Patent 11919903 Polymorphs

‌

US Patent 11911388 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

‌

US Patent 11911387 Vasoprotective and cardioprotective antidiabetic therapy

Patent Primary Examiner

‌

Mark L. Berch

Patent abstract

The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, which are of formula I

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7235538 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API